aegera

  1. T

    Human Genome Sciences And Aegera Therapeutics Announce Initiation Of Clinical Trial O

    Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors. More...
    • tD33NAt
    • Thread
    • aegera announce clinical genome human initiation sciences therapeutics trial
    • Replies: 0
    • Forum: Health and Fitness
  2. T

    Human Genome Sciences And Aegera Therapeutics Announce Initiation Of Clinical Trial O

    Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors. More...
    • tD33NAt
    • Thread
    • aegera announce clinical genome human initiation sciences therapeutics trial
    • Replies: 0
    • Forum: Health and Fitness
Back
Top